Eli Lilly (LLY) is highlighted as one of the top 10 safe stocks recommended for long-term investment in 2026.

Analysts have expressed conflicting sentiments regarding several healthcare companies, including Pacific Edge Limited, Kura Oncology, and Eli Lilly & Co. Their differing opinions reflect varied outlooks on these firms.

GC Biopharma announced it will transfer its US affiliate Curevo Vaccine to Eli Lilly and Company in a deal potentially worth up to $1.5 billion, granting Lilly rights to amezosvatein.

Goldman Sachs has advised investors looking to diversify away from the artificial intelligence trade to consider stocks less correlated with the AI frenzy. The firm highlighted companies such as Eli Lilly and Fortinet as potential options.

Eli Lilly has reported positive Phase 3 clinical trial results for its investigational obesity treatment, Retatrutide, with its latest GLP-1 drug showing significant promise as a powerful weapon in the fight against obesity.

Eli Lilly's new obesity drug has demonstrated superior efficacy in trials, helping patients lose over 30% of their body weight and surpassing the performance of Ozempic and Mounjaro.

Eli Lilly announced that its next-generation obesity drug has demonstrated significant efficacy, helping patients lose an average of 28% of their body weight.

Pharmaceutical giant Eli Lilly has announced a deal to acquire Engage Bio, a company focused on non-viral genetic medicines, for up to $202 million. The acquisition aims to expand Lilly's portfolio in genetic medicine.

Investors in Eli Lilly and Company (LLY) are being advised to consider the broader context of the company's performance and future. The recommendation suggests looking beyond short-term fluctuations to long-term potential.

An article evaluates whether Eli Lilly and Company (LLY) is a good stock investment opportunity for buyers.

Barclays analysts have issued a report indicating a reinforced long-term growth narrative for Eli Lilly and Company (LLY), suggesting positive prospects for the pharmaceutical giant.

Early investors in Eli Lilly stock are now reportedly earning a 9% dividend yield-on-cost, indicating strong returns for long-term shareholders.

An analysis highlights Eli Lilly (LLY) as one of the best stocks to consider buying for investment over the next 15 years.

Cantor Fitzgerald and Raymond James have increased their price targets for Eli Lilly and Visa, respectively. These adjustments follow the companies' strong first-quarter earnings calls and solid results.

Wall Street analysts are assessing the performance and outlook of Eli Lilly stock. Their opinions provide insights into the pharmaceutical company's investment potential.

At Eli Lilly's annual meeting, directors were re-elected while proposed governance changes failed to pass, with CEO David Ricks highlighting a significant 45% jump in revenue for the pharmaceutical giant.

Early performance of Novo Nordisk's Wegovy pill is prompting investors to reconsider Eli Lilly & Co.'s previously assumed dominance in the GLP-1 pill market.

The French drug safety agency ANSM has fined pharmaceutical companies Novo Nordisk and Eli Lilly for advertisements related to weight management drugs in France.

Pharmaceutical companies Novo Nordisk and Eli Lilly have been fined hundreds of thousands of euros for failing to comply with advertising restrictions for prescription-only anti-obesity medications.

Truist has reaffirmed its 'Buy' rating for Eli Lilly (LLY) following the success of a recent trial. The positive trial results are expected to bolster investor confidence in the pharmaceutical giant.

A "Fast Money" panel has suggested that Novo Nordisk is now a more compelling investment than Eli Lilly, particularly after Novo Nordisk's stock experienced a significant 70% decline. The discussion centered on the relative value and future prospects of the two pharmaceutical giants.

Pharmaceutical company Eli Lilly announced strong financial results for the first quarter of 2026, with significant growth attributed to the performance of its key drugs, Mounjaro and Zepbound.

Traders are reportedly anticipating significant movement in Eli Lilly's stock following the company's latest earnings report. The article discusses expectations for the pharmaceutical giant's market performance.

Investors in Eli Lilly are keenly awaiting further information and insights regarding the drug Foundayo, following the release of its early launch data.

Novartis, Amgen, and Eli Lilly are investing in research to target a specific, lesser-known type of cholesterol, hoping it will lead to the next generation of blockbuster heart medications.

Pharmaceutical giant Eli Lilly is set to acquire Ajax Therapeutics in a deal potentially valued at up to $2.3 billion, expanding its therapeutic portfolio.

Analysts are assessing the investment potential of several healthcare and pharmaceutical companies, including Eli Lilly, IGC Pharma, and 60 Degrees Pharmaceuticals. They are providing insights and recommendations for investors considering these stocks.

Several stocks, including Intel, AMD, Charter, Hims & Hers, and Eli Lilly, are experiencing notable movements in midday trading.

Eli Lilly's stock experienced a decline following a challenging week for its drug Foundayo, while the FDA announced plans to issue vouchers to accelerate research into psychedelic-based medicines.

Pharmaceutical company Eli Lilly has ended its license agreement with Rigel Pharmaceuticals concerning the drug ocadusertib.

This article investigates the reasons behind the decline in Eli Lilly's stock price today.

Eli Lilly has agreed to acquire the cancer biotechnology company Kelonia in a deal valued at up to $7 billion. This acquisition aims to expand Lilly's portfolio in cancer drug development.

Eli Lilly is reportedly close to finalizing a deal to acquire a cancer biotechnology company, signaling a strategic expansion in its oncology portfolio.

An analysis compares Eli Lilly and Viking Therapeutics to determine which pharmaceutical stock presents a better long-term investment opportunity.

Morgan Stanley has increased its price target for Eli Lilly and Company (LLY), based on updated assumptions within its biopharma financial model.

The UAE has become one of the first countries to approve Eli Lilly's once-daily oral obesity pill, Foundayo (orforglipron), a GLP-1 receptor agonist that mimics natural hormones to regulate appetite.

Eli Lilly has disclosed the results of a late-stage study for its Type 2 Diabetes treatment. The announcement provides new data on the efficacy and safety of the drug.

An analysis explores the factors contributing to Eli Lilly's stock performance and its potential to reach $2,000.

American pharmaceutical company Eli Lilly has launched a new weight-loss drug, intensifying competition with Novo Nordisk's popular Wegovy. Experts believe the Danish pharmaceutical company remains strong in the battle for market share.

Investors are anticipating the release of Eli Lilly's next quarterly earnings report, with analysts providing expectations for the pharmaceutical giant's performance.

The proliferation of generic drug copies from India is reportedly having a detrimental effect on the sales figures of pharmaceutical giant Eli Lilly.

Investors are evaluating whether Eli Lilly's stock is a good buy following a recent brand new drug approval.

An analysis compares Eli Lilly and JPMorgan Chase, speculating which of the two major companies is more likely to be the first to achieve a $1 trillion market capitalization.

Jim Cramer shared his opinion that Eli Lilly's new weight loss medication is poised to become a highly successful product in the market.

Eli Lilly (LLY) has received FDA approval for its new weight management pill, Foundayo, marking a significant development in the treatment of obesity.

Eli Lilly (LLY) has announced its intention to acquire Centessa Pharmaceuticals in a deal valued at $7.8 billion.

Despite Novo Nordisk's current market lead, Wall Street analysts are projecting a multi-billion dollar debut for Eli Lilly's new obesity pill.

Centessa (CNTA) shares have soared to an all-time high, experiencing a 38% upside following its merger with Eli Lilly, indicating a significant positive market reaction to the corporate development.

Eli Lilly has announced its intention to acquire Centessa Pharmaceuticals in an initial deal valued at $6.3 billion.

Eli Lilly and Company (LLY) has seen continued financial gains, largely attributed to the strong performance of its incretin portfolio.

Pharmaceutical giant Eli Lilly has finalized a deal with InSilico, a company specializing in artificial intelligence, to collaborate on drug discovery efforts.

An analysis of the PPH ETF highlights drug pricing policy and the market concentration of pharmaceutical giant Eli Lilly as two significant risks for investors to monitor in 2026.

An analysis compares the stock performance of pharmaceutical giants Eli Lilly and Novo Nordisk, focusing on which company presents a better investment opportunity in the rapidly growing obesity drug market.

Eli Lilly (LLY) has seen gains driven by the strong performance and growth of its GLP-1 franchises drugs.

More than 80 global executives, including leaders from Apple and Eli Lilly, traveled to Beijing to attend the state-organized China Development Forum, aiming to revamp their push into the world's second-largest economy.

This week's notable healthcare headlines focus on key developments concerning pharmaceutical companies such as Eli Lilly, Novo Nordisk, and Novartis.

Eli Lilly has released new obesity data that could set a higher standard for the industry, leading CVS to announce it will restore coverage for Zepbound and add Eli Lilly's obesity pill to its drug plans. This development is expected to significantly impact the obesity treatment market.

Pharmaceutical giant Eli Lilly is making a substantial $4 billion investment in vaccine research and development.

Eli Lilly's new gene-editing therapy has demonstrated significant potential in preventing heart attacks by reducing LDL cholesterol levels by 62% in trials.

CNBC reports that Eli Lilly has announced robust Phase 3 trial results for its drug Retatrutide, indicating promising efficacy.

Eli Lilly (LLY) has reported positive Phase 3 clinical trial results for its investigational obesity treatment, Retatrutide, marking a significant development in the pharmaceutical company's pipeline.

Eli Lilly (LLY) is experiencing robust growth, primarily driven by the momentum of its drug Mounjaro and increasing demand for GLP-1 medications, leading Barclays to maintain a bullish outlook on the company.

Selskabet Eli Lilly vil have fat i svært overvægtige patienter med sit middel retatrutide, skriver Reuters.

Analysts are speculating on the future trajectory of Eli Lilly's stock, with some suggesting it could reach $2,000. The article likely discusses factors driving its current performance and potential for further growth.

Eli Lilly (LLY) has released new results from its late-stage clinical trials for a weight loss treatment, potentially impacting the market for obesity drugs.

An analyst has raised Eli Lilly (LLY) price target by $52 following the company's Q1 report.

An analyst suggests that a new weight-loss drug challenger has the potential to replicate the successful playbook of pharmaceutical giant Eli Lilly.

Analysts have provided a prediction for where Eli Lilly's stock price is expected to close by the end of the current year.

The article compares Pfizer and Eli Lilly's distinct strategies and investment approaches regarding mergers and acquisitions within the pharmaceutical industry.

Eli Lilly's new obesity medication has recorded over 7,000 prescriptions in its fourth week on the market, indicating a modest initial uptake.

The Icelandic Medicines Agency is investigating advertisements for prescription drugs that have appeared in Icelandic media, following similar actions where the French drug safety agency fined Novo Nordisk and Eli Lilly.

Eli Lilly now boasts the world's best-selling drug, leading to discussions among investors about whether this makes the company's stock an automatic buy.

Eli Lilly's stock experienced fluctuations after the FDA released a report concerning liver failure associated with one of its GLP-1 drugs.

Eli Lilly has commenced a high-grade bond sale as part of its strategy to secure funding for upcoming deals and acquisitions.

Eli Lilly has significantly increased its market share in the GLP-1 segment, with Mounjaro's revenue soaring by 125%. The company now holds 60% of the GLP-1 market.

Financial analyst Jim Cramer has stated his belief that Eli Lilly's weight loss pill is superior to those offered by Novo Nordisk.

Shares of pharmaceutical company Eli Lilly are under pressure following a report of a serious adverse event related to its drug, Foundayo.

Pharmaceutical company Eli Lilly has released news that is expected to be highly favorable for its shareholders.

This week's notable healthcare headlines focus on key industry players such as Merck, Eli Lilly, and GE HealthCare.

Bank of America analysts have indicated a positive outlook for Eli Lilly stock, suggesting further potential for growth.

Analysts have highlighted Eli Lilly and Company (LLY) as one of the best drug stocks to consider for investment. The report outlines the reasons behind this positive assessment.

Eli Lilly's stock performance is being significantly lifted by strong sales of its GLP-1 drugs, prompting analysis on whether LLY stock is a good investment.

The U.S. FDA has proposed new restrictions on the mass compounding of weight-loss drugs manufactured by Novo Nordisk and Eli Lilly.

Eli Lilly has increased its annual profit forecast, attributing the upward revision to the strong growth and demand for its GLP-1 class of drugs.

Guggenheim has increased its price target for Eli Lilly (LLY), attributing the adjustment to the pharmaceutical company's recent series of acquisition deals.

A prominent Wall Street analyst has indicated that Eli Lilly's stock, currently priced at $870, may be undervalued.

Analysts remain bullish on Eli Lilly ahead of its Q1 earnings report, with particular focus on the company's obesity drug portfolio and the drug Foundayo. The preview suggests strong performance expectations driven by these key areas.

The article discusses whether investors should consider buying Eli Lilly stock following a recent dip in its price. It provides analysis for potential investment decisions regarding the pharmaceutical company.

Investment analysts have identified Eli Lilly and Company (LLY) as a highly recommended stock, citing its potential as a low-risk, high-growth option even during market downturns.

Eli Lilly's stock performance saw a significant decline on Friday, prompting analysis into the reasons behind its market movement.

Shares of Eli Lilly & Co. fell in premarket trading after new industry prescription data for its blockbuster obesity drug Zepbound disappointed Wall Street investors.

An article advises investors not to be concerned about the prospects of Eli Lilly (LLY) and Company's Foundayo treatment, implying positive outlooks for the drug.

Health insurers are raising questions about a new Medicare program that will offer GLP-1 medications to seniors for $50 per month, leading to a drop in shares for pharmaceutical companies like Novo Nordisk and Eli Lilly amid concerns over coverage plans.

Eli Lilly is capitalizing on its GLP-1 drug windfall, while Honeywell is shedding a lower-margin business unit, as part of daily market updates from the Investing Club.

Pharmaceutical giant Eli Lilly is reportedly in advanced discussions to acquire Kelonia Therapeutics in a deal valued at over $2 billion. The potential acquisition was first reported by the Wall Street Journal.

Eli Lilly has announced that the U.S. Food and Drug Administration (FDA) has requested additional clinical data regarding its experimental obesity pill, potentially delaying its approval.

Pharmaceutical giant Eli Lilly is reportedly on the cusp of a major development, described as a potential 'game-changer' in its 150-year history, signaling a significant shift for the company.

Eli Lilly's new weight loss medication reportedly garnered close to 1,400 prescriptions in its initial week following its launch, indicating early demand for the drug.

A recent $6.3 billion deal is being analyzed for its potential to be a significant game-changer for the pharmaceutical company Eli Lilly.

Eli Lilly is reportedly leaving competitor Novo Nordisk behind in a significant pharmaceutical market race, likely driven by their respective drug developments and market performance.

Following regulatory approval for its new weight loss pill, investors are evaluating the potential for Eli Lilly's stock to surge.

Eli Lilly is reportedly not just replacing its drug Zepbound but is actively expanding its presence to build a dominant position in the broader obesity treatment market.

Eli Lilly is losing market share in India's GLP-1 market due to the influx of cheap semaglutide generics, while Novo Nordisk maintains its position through price cuts for Ozempic and Wegovy.

Financial analyst Jim Cramer discussed Eli Lilly's (LLY) potential dominance in the weight loss market and how Novo Nordisk (NVO) might face increased competition from it.

AC Immune's stock experienced a rise after the company announced an amendment to its licensing deal with pharmaceutical giant Eli Lilly.

Eli Lilly's trajectory towards a $1 trillion valuation is seen as directly tied to the ongoing boom in artificial intelligence. Analysts suggest that AI advancements will play a significant role in the pharmaceutical company's future growth and market capitalization.

Eli Lilly's new GLP-1 weight-loss pill, Foundayo, which is the first oral GLP-1 not requiring fasting, has been approved by the Food and Drug Administration and has shown effectiveness in clinical trials, with one user losing 25 pounds.

An analysis explores whether Eli Lilly and Company (LLY) represents the optimal pharmaceutical stock investment opportunity at the current time.

The U.S. Food and Drug Administration has granted market approval to Eli Lilly for its new weight-loss pill, making it available soon.

Options traders are actively engaging with pharmaceutical stocks following a significant buyout by Eli Lilly, indicating market speculation and potential shifts in the sector.

Eli Lilly has announced its intention to acquire Centessa Pharmaceuticals for an initial sum of $6.3 billion, expanding its portfolio in the pharmaceutical sector.

Eli Lilly's CEO has indicated that a particular development could significantly transform the company's business operations and future prospects.

Novo Nordisk (NVO) shares have gone up since Jim Cramer stated he was a buyer of the stock.

Pharmaceutical giant Eli Lilly has entered into a strategic agreement with InSilico, a company specializing in artificial intelligence, to collaborate on AI-driven drug discovery initiatives, aiming to accelerate the development of new medicines.

Jefferies has reiterated its 'Buy' rating for pharmaceutical giant Eli Lilly and Company (LLY).

An analysis highlights a key reason why Eli Lilly's stock is still considered a favorable investment opportunity.

Eli Lilly announced that its once-monthly injectable treatment for eczema delivered durable disease control in clinical trials, offering a potential new option for patients.

Investors looking to 'buy the dip' on Eli Lilly stock are advised to consider a specific low-cost Vanguard ETF as an investment option.

Analysts have provided projections on the potential upside for Eli Lilly stock, offering insights into its future market performance.

An investment analysis explores whether investors should consider buying Eli Lilly stock before April 10, providing insights into its market position.

CVS Health has reinstated coverage for Eli Lilly's weight-loss drug Zepbound.

Eli Lilly is reportedly undertaking a $20 billion buying spree as the pharmaceutical giant seeks to define its next strategic phase.

A summary of significant healthcare news for the week, highlighting companies like UnitedHealth, Boston Scientific, and Eli Lilly.

Eli Lilly announced clinical trial results for retatrutide, its next gen obesity drug. The drug helped study participants lose 70 lbs over 80 weeks, making it more powerful than Zepbound and Wegovy.

Pharmaceutical giant Eli Lilly has filed a civil lawsuit, claiming to be the victim of a $200 million drug rebate fraud scheme allegedly involving Pentecostal church bishops and various businesses.

New data has reportedly increased confidence in Eli Lilly's obesity medication, as highlighted in an actionable afternoon update for investors, which also touched upon Google's new AI features.

For a century and a half, Eli Lilly and Company has been bringing innovative therapies to the global market for some of the most pressing and widespread conditions, such as diabetes, obesity, Alzheimer's disease, and cancer.

Following the success of Eli Lilly's Mounjaro, Korean drugmakers are intensifying efforts to develop monthly obesity shots, aiming for less frequent injections in the competitive market.

Financial commentator Jim Cramer has provided a range of stock recommendations, advising on whether to buy, hold, or avoid various companies including TJX, Caterpillar, Eli Lilly, and Cloudflare. He also expressed regret over selling Cisco and cautioned against buying certain stocks at their current highs.

Pharmaceutical company Eli Lilly has launched its Alzheimer's drug, donanemab, in India, making it available for patients in the country.

France's National Agency for the Safety of Medicine and Health Products (ANSM) has sanctioned pharmaceutical companies Novo Nordisk and Eli Lilly, ruling that their 'awareness initiatives' were in fact covert product promotions.

An analysis explores whether Eli Lilly could become the first $2 trillion healthcare stock, identifying three key catalysts that could drive its growth.

Financial analysts have identified several companies, including Comfort Systems USA, Eli Lilly, and Meta Platforms, as strong buy growth stocks within the S&P 500 for potential investment.

Wolfe Research suggests that the market's reaction to Eli Lilly's (LLY) Foundayo report appears to be excessive, indicating a potential overcorrection in the stock price.

Following its recent earnings report, Eli Lilly's stock continues to be rated as a 'Buy' by analysts.

Barclays has increased its price target for Eli Lilly to $1,400, highlighting the strong momentum of its drug Tirzepatide as a key factor.

An analysis delves into the reasons behind Eli Lilly's fluctuating stock performance, following a significant surge in its share price after last week's earnings report.

Eli Lilly has announced a dividend of $1.73 per share, a key financial update for investors.

French regulators have issued fines to pharmaceutical companies Novo Nordisk France and Lilly France for advertising anti-obesity treatments to the general public, which is prohibited under French law.

Jim Cramer provided his latest insights on a diverse portfolio of stocks, commenting on companies like Oklo, Reddit, Palantir, Meta, Microsoft, Amazon, Alphabet, Mastercard, Intuitive Surgical, Apple, Caterpillar, and Arm Holdings. He discussed their performance, market trends, and investment potential.

Eli Lilly is benefiting from strong consumer demand for its weight loss drugs, with analyst Gary Black suggesting the company's valuation remains compelling.

Jim Cramer analyzed the stock market's performance after a challenging earnings week, noting its resilience but cautioning that further difficulties may lie ahead. He also identified Apple and Eli Lilly as stocks with continued growth potential and provided his top market observations for the upcoming trading day.

Eli Lilly reported a significant 56% surge in sales, primarily attributed to the booming demand for GLP-1 drugs, which overshadowed the impact of lower prices.

Eli Lilly has projected its 2026 revenue to be between $82 billion and $85 billion, with non-GAAP earnings per share estimated at $35.50 to $37. These projections come as the company begins the launch of its new product, Foundayo.

Eli Lilly has raised its profit and sales forecasts, driven by surging demand for its weight-loss drugs, including a new obesity pill. This increased demand is helping to offset pricing pressures and boost the company's financial outlook.

Jim Cramer expressed his belief that Novo Nordisk is poised to lose significant market share in the pill segment to competitor Eli Lilly, highlighting the competitive landscape in the pharmaceutical industry.

Eli Lilly and Company (LLY) experienced a stock decline in the first quarter, even as the pharmaceutical giant reported strong overall results.

Jim Cramer expressed his belief that Eli Lilly 'will tell a good story' when the company reports its earnings.

This week's significant healthcare news highlights developments concerning major players like UnitedHealth, Eli Lilly, and Organon.

Eli Lilly's obesity pill recorded a modest performance in its second week on the market, as competition with pharmaceutical rival Novo Nordisk intensifies.

Eli Lilly's new obesity pill has recorded nearly 4,000 prescriptions in its second week post-launch, with some reports characterizing its initial uptake as slow in comparison to rivals.

Eli Lilly (LLY) has been identified as one of the eight best beginner stocks to buy, according to a recent market analysis.

Eli Lilly is reportedly eyeing a $7 billion deal to acquire Kelonia, with $3.25 billion to be paid upfront.

The article discusses whether Eli Lilly's new GLP-1 pill could drive the company's stock valuation back to the $1 trillion mark, examining its market potential.

Pharmaceutical giant Eli Lilly is reportedly close to acquiring Kelonia Therapeutics in a deal valued at over $2 billion, aiming to bolster its cancer treatment pipeline.

The future of obesity treatment is evolving with new weight-loss drugs, including those in pill form, and advancements in personalized therapy. Eli Lilly's CEO projects that these medications could eventually reach about half of potential users at their peak.

Eli Lilly's CEO has voiced disappointment that only a small fraction of Americans are currently using GLP-1 medications, a class of drugs used for conditions like diabetes and weight loss. The statement highlights concerns about the accessibility or uptake of these treatments.

Eli Lilly's new drug, Foundayo, achieved 1,390 prescriptions during its first week on the market, according to a Reuters report.

Eli Lilly is set to acquire CrossBridge Bio, a move aimed at bolstering its oncology drug development pipeline. This acquisition is expected to enhance Eli Lilly's capabilities and offerings in the cancer treatment sector.

This article provides a summary of notable healthcare headlines for the week, focusing on companies such as Organon, Eli Lilly, and Gilead.

Eli Lilly has taken the lead in the obesity drug race against Novo Nordisk, whose GLP-1 pill momentum is now facing a pricing test, according to a leading bank.

A report indicates that the availability of inexpensive semaglutide copies in India is posing a significant challenge to pharmaceutical giants Novo Nordisk and Eli Lilly, potentially eroding their market lead.

Novo Nordisk has launched the high-dose version of its GLP-1 injection, Wegovy, at a price point $50 lower than Eli Lilly's competing drug, Zepbound. This strategic pricing aims to position Wegovy competitively in the market.

Eli Lilly and Company (LLY) saw its price target raised by analysts following the FDA's approval of its new drug, Fundayo.

US tariffs: Pharmaceutical industry fears for European sites +++ Industry sees growing opportunities in defense +++ Eli Lilly's weight loss pill receives US approval +++ Company news live blog.

Pharmaceutical giant Eli Lilly has struck a deal with InSilico for AI-powered drug discovery, as reported by the Wall Street Journal.

Eli Lilly has introduced its Zepbound KwikPen for weight management, making it available through the telehealth platform Ro.

Eli Lilly and Company's stock significantly outperformed the market today, leading to investor interest and analysis.

Eli Lilly announced its intention to acquire Centessa Pharmaceuticals for an initial $6.3 billion, a deal confirmed by recent reports, aiming to bolster its portfolio of sleep medicines and narcolepsy drugs.

Eli Lilly is deepening its commitment to artificial intelligence in drug discovery by expanding its existing partnership with Insilico Medicine.

US pharmaceutical giant Eli Lilly is reportedly pushing for higher drug prices from the NHS, linking the increases to its investment plans within the United Kingdom and expressing optimism about ongoing talks with ministers.

Eli Lilly has struck a deal with InSilico, leveraging artificial intelligence for drug discovery in a move to accelerate pharmaceutical development.

Eli Lilly & Co. is sponsoring an ESPN2 reunion special celebrating the heroic coach Pat Summitt, aiming to find new ways to tell medical stories and connect with audiences beyond traditional commercials.

The Janus Henderson Forty Fund has provided updates regarding its investment position and outlook on pharmaceutical giant Eli Lilly and Company (LLY).

Jim Cramer has offered his perspective on whether Eli Lilly (LLY) stands out as the best healthcare stock for investors to consider.

Morgan Stanley has reaffirmed its 'Overweight' rating on Eli Lilly (LLY), highlighting the substantial growth potential of the company's new platform. This positive outlook is based on anticipated future developments.

This week's notable healthcare headlines focus on key developments concerning pharmaceutical companies such as Eli Lilly, which is expanding Zepbound access, along with Novo Nordisk and Novartis.